United States - English - NLM (National Library of Medicine)

xellia pharmaceuticals aps - colistimethate (unii: dl2r53p963) (colistin - unii:z67x93hjg1) - colistin 150 mg in 2 ml - colistimethate for injection, usp is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa. this antibiotic is not indicated for infections due to proteus or neisseria . colistimethate for injection, usp has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa . colistimethate for injection, usp may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection, usp and other antibacterial drugs, colistimethate for injection, usp should be used only to treat or

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - colistimethate sodium (unii: xw0e5ys77g) (colistimethate - unii:dl2r53p963) - colistin 150 mg in 2 ml - coly-mycin m parenteral is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. it is particularly indicated when the infection is caused by sensitive strains of pseudomonas aeruginosa . this antibiotic is not indicated for infections due to proteus or neisseria . coly-mycin m parenteral has proven clinically effective in treatment of infections due to the following gram-negative organisms: enterobacter aerogenes, escherichia coli, klebsiella pneumoniae and pseudomonas aeruginosa. coly-mycin m parenteral may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. to reduce the development of drug-resistant bacteria and maintain the effectiveness of coly-mycin m and other antibacterial drugs, coly-mycin m should be used only to treat or prevent infections that are proven or strongly suspected to be caused by s

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - colistimethate sodium - powder for solution for injection - 1000000unit

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - colistimethate sodium 384.6 mg/ml - powder for injection - 150 mg/2ml - active: colistimethate sodium 384.6 mg/ml - the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli; particularly when the infection is caused by sensitive strains of pseudomonas aeruginosa, and the following gram-negative organisms; aerobacter aerogenes, escherichia coli, klebsiella pneumoniae. pending results of appropriate bacteriologic cultures and sensitivity tests, colistimethate sodium may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms.

European Union - English - myHealthbox

forest laboratories uk ltd - colistimethate sodium - inhalation powder, hard capsule - each capsule contains 1662500iu (approximately equal to 125mg) of colistimethate sodium - cystic fibrosis - antibacterials for systemic use - colobreathe is indicated for the management of chronic pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis (cf) aged 6 years and older

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zulat pharmacy sdn. bhd. - colistimethate sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - colistimethate sodium, quantity: 1 million iu - inhalation - excipient ingredients: - colistimixin phebra powder for nebuliser solution is indicated for the treatment of colonisation and infections of the lung due to susceptible pseudomonas aeruginosa in patients with cystic fibrosis. consideration should be given to official guidance on the appropriate use of antibacterial agents.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - colistimethate sodium - powder for solution for infusion or injection - colistimethate sodium 1,000,000 iu - antibacterials for systemic use

European Union - English - EMA (European Medicines Agency)

teva b.v. - colistimethate sodium - cystic fibrosis - antibacterials for systemic use, - colobreathe is indicated for the management of chronic pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis (cf) aged six years and older.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - English - Ministry of Health

rafa laboratories ltd - colistimethate sodium - powder for concentrate for infusion - colistimethate sodium 1000000 u/vial - colistin - colistin - antibiotic for treatment of infections caused by micro-organisms sensitive to colistin.